The association between body mass index and mortality in breast cancer patients receiving pembrolizumab.

IF 2.5 3区医学 Q3 ONCOLOGY

Oncology Pub Date : 2024-11-12 DOI:10.1159/000542542

Cho-Han Chiang, Xiaocao Xu, Ahmed Shahid, Junmin Song, Kuan-Yu Chi, Yu-Cheng Chang, Yu Chang, Cho-Hung Chiang, Shuwen Lin

{"title":"The association between body mass index and mortality in breast cancer patients receiving pembrolizumab.","authors":"Cho-Han Chiang, Xiaocao Xu, Ahmed Shahid, Junmin Song, Kuan-Yu Chi, Yu-Cheng Chang, Yu Chang, Cho-Hung Chiang, Shuwen Lin","doi":"10.1159/000542542","DOIUrl":null,"url":null,"abstract":"Introduction: A higher body mass index (BMI) has been associated with a better response and overall survival in patients with lung cancer or melanoma receiving immune checkpoint inhibitors (ICIs). Pembrolizumab has been approved for the use of breast cancer but its relationship with survival outcomes is unclear.Methods: We conducted a retrospective, propensity score-matched cohort study using the TriNetX Analytics Network database, which contains de-identified data from over 120 participating healthcare institutions. We included all adult female patients with breast cancer who received pembrolizumab. We excluded patients who were prescribed endocrine or human epidermal growth factor receptor 2 targeted therapies. We compared the 1-year all-cause mortality between patients who were overweight or obese (BMI ≥ 25 kg/m2) and those who were normal weight (BMI < 25 kg/m2). We matched patients on predetermined variables including age, race, breast cancer-directed therapy, cardiovascular and diabetes medications, and underlying comorbidities.Results: We identified 1628 eligible patients, of whom 1163 had a BMI ≥ 25 kg/m2 and 465 had a BMI < 25 kg/m2. After propensity score matching, 410 patients in each cohort were well-balanced for demographics, breast cancer-directed therapy, and underlying comorbidities. The mean ages for patients with BMI ≥ 25 kg/m2 and BMI < 25 kg/m2 were 56.7±14.0 and 56.9±15.0, respectively. Over a median follow-up of 1 year, 28 and 53 patients died in the BMI ≥ 25 kg/m2 and BMI < 25 kg/m2 cohorts, respectively. Patients with BMI ≥ 25 kg/m2 had a 49% lower risk of all-cause mortality compared with those with BMI < 25 kg/m2 (Hazard ratio (HR), 0.51 [95% CI: 0.33-0.81]).Conclusions: A BMI ≥ 25 kg/m2 was associated with a lower all-cause mortality among breast cancer patients receiving pembrolizumab.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-9"},"PeriodicalIF":2.5000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000542542","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: A higher body mass index (BMI) has been associated with a better response and overall survival in patients with lung cancer or melanoma receiving immune checkpoint inhibitors (ICIs). Pembrolizumab has been approved for the use of breast cancer but its relationship with survival outcomes is unclear.

Methods: We conducted a retrospective, propensity score-matched cohort study using the TriNetX Analytics Network database, which contains de-identified data from over 120 participating healthcare institutions. We included all adult female patients with breast cancer who received pembrolizumab. We excluded patients who were prescribed endocrine or human epidermal growth factor receptor 2 targeted therapies. We compared the 1-year all-cause mortality between patients who were overweight or obese (BMI ≥ 25 kg/m2) and those who were normal weight (BMI < 25 kg/m2). We matched patients on predetermined variables including age, race, breast cancer-directed therapy, cardiovascular and diabetes medications, and underlying comorbidities.

Results: We identified 1628 eligible patients, of whom 1163 had a BMI ≥ 25 kg/m2 and 465 had a BMI < 25 kg/m2. After propensity score matching, 410 patients in each cohort were well-balanced for demographics, breast cancer-directed therapy, and underlying comorbidities. The mean ages for patients with BMI ≥ 25 kg/m2 and BMI < 25 kg/m2 were 56.7±14.0 and 56.9±15.0, respectively. Over a median follow-up of 1 year, 28 and 53 patients died in the BMI ≥ 25 kg/m2 and BMI < 25 kg/m2 cohorts, respectively. Patients with BMI ≥ 25 kg/m2 had a 49% lower risk of all-cause mortality compared with those with BMI < 25 kg/m2 (Hazard ratio (HR), 0.51 [95% CI: 0.33-0.81]).

Conclusions: A BMI ≥ 25 kg/m2 was associated with a lower all-cause mortality among breast cancer patients receiving pembrolizumab.

查看原文本刊更多论文

接受 pembrolizumab 治疗的乳腺癌患者的体重指数与死亡率之间的关系。

导言：在接受免疫检查点抑制剂（ICIs）治疗的肺癌或黑色素瘤患者中，较高的体重指数（BMI）与较好的反应和总生存率相关。Pembrolizumab已被批准用于乳腺癌治疗，但其与生存结果的关系尚不清楚：我们利用 TriNetX 分析网络数据库开展了一项倾向得分匹配队列回顾性研究，该数据库包含来自 120 多家参与医疗机构的去标识化数据。我们纳入了所有接受过彭博利珠单抗治疗的成年女性乳腺癌患者。我们排除了接受内分泌或人类表皮生长因子受体 2 靶向治疗的患者。我们比较了超重或肥胖（体重指数≥ 25 kg/m2）患者与体重正常（体重指数< 25 kg/m2）患者的 1 年全因死亡率。我们根据预先确定的变量（包括年龄、种族、乳腺癌定向治疗、心血管和糖尿病药物以及基础合并症）对患者进行了配对：我们确定了1628名符合条件的患者，其中1163人的体重指数≥25 kg/m2，465人的体重指数<25 kg/m2。经过倾向评分匹配后，每个队列中的 410 名患者在人口统计学、乳腺癌定向治疗和基础合并症方面都非常均衡。体重指数≥25 kg/m2和体重指数＜25 kg/m2患者的平均年龄分别为（56.7±14.0）岁和（56.9±15.0）岁。在中位随访 1 年期间，BMI ≥ 25 kg/m2 和 BMI < 25 kg/m2 组别分别有 28 和 53 名患者死亡。与 BMI < 25 kg/m2 的患者相比，BMI ≥ 25 kg/m2 患者的全因死亡风险降低了 49%（危险比 (HR)，0.51 [95% CI: 0.33-0.81]）：BMI≥25 kg/m2与接受pembrolizumab治疗的乳腺癌患者全因死亡率降低有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.